Morse Asset Management Inc Has $3.75 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Morse Asset Management Inc raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 562.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,292 shares of the biopharmaceutical company's stock after buying an additional 56,292 shares during the quarter. Morse Asset Management Inc's holdings in Bristol-Myers Squibb were worth $3,749,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Czech National Bank grew its position in shares of Bristol-Myers Squibb by 6.5% in the 4th quarter. Czech National Bank now owns 439,749 shares of the biopharmaceutical company's stock valued at $24,872,000 after purchasing an additional 26,747 shares during the period. Aprio Wealth Management LLC lifted its stake in Bristol-Myers Squibb by 72.9% in the 4th quarter. Aprio Wealth Management LLC now owns 8,282 shares of the biopharmaceutical company's stock valued at $468,000 after acquiring an additional 3,493 shares in the last quarter. Fiduciary Alliance LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $253,000. Trust Co. of Toledo NA OH lifted its stake in Bristol-Myers Squibb by 21.8% in the 4th quarter. Trust Co. of Toledo NA OH now owns 46,679 shares of the biopharmaceutical company's stock valued at $2,640,000 after acquiring an additional 8,341 shares in the last quarter. Finally, Brookstone Capital Management lifted its stake in Bristol-Myers Squibb by 11.0% in the 4th quarter. Brookstone Capital Management now owns 186,155 shares of the biopharmaceutical company's stock valued at $10,529,000 after acquiring an additional 18,516 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.96 on Friday, reaching $46.77. The stock had a trading volume of 12,103,063 shares, compared to its average volume of 13,242,296. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm has a fifty day moving average of $53.35 and a two-hundred day moving average of $56.01. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a market cap of $95.18 billion, a P/E ratio of -10.58, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($4.40) EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.30%. Bristol-Myers Squibb's payout ratio is 92.88%.

Wall Street Analyst Weigh In

Several research firms have commented on BMY. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Piper Sandler began coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.